SOST and neoplasm: To investigate whether suppression of sclerostin may lose growth advantage in vivo, MDA-MB-231 cells (5 × 106 in 30 μl PBS) were injected into the bone marrow space of BALB/c-nu/nu mice and tumor volume was measured starting at 1 week later.